Labcorp Holdings Inc. Q3 FY2025 earnings call

Management Statement and Operational Highlights

• Financial Results: Revenue totaled $3.6 billion, up 8.6% year-over-year. Adjusted operating income was $513 million, 14.4% of revenue. Adjusted EPS was $4.18, up 19% year-over-year. Free cash flow was $281 million.
• Strategic Acquisitions and Partnerships: Signed agreements to acquire assets from Empire City Laboratories, Laboratory Alliance of Central New York, and to manage Crouse Health's inpatient labs, with expected closings in Q1 2026. Also, acquired select oncology and clinical testing assets from BioReference Health.
• Innovation and Testing Capabilities: Introduced OmniSeq INSIGHT for ovarian tumors, PGDx elio tissue complete with CE marking, Geneoscopy's ColoSense with FDA approval, and expanded Invitae genetic tests via Epic Aura.
• Technology Adoption: Launched Labcorp Test Finder using generative AI, digitalized pathology workflows with Roche, and deployed AI for cytology and microbiology to improve turnaround times.

Segment Performance

• Diagnostics Laboratories: Revenue was $2.8 billion, up 8.5% year-over-year with organic growth of 6.3% and acquisitions of 2.2%. Adjusted operating income was $450 million, 16.3% of revenue, up 110 basis points. Total volume increased 4.7% with organic volume contributing 3.5%.
• Biopharma Laboratory Services (BLS): Revenue was $799 million, up 8.3% year-over-year due to organic revenue growth of 5.3% and foreign currency translation of 3%. Central Labs grew 10% (7% constant currency), while Early Development was lower due to delayed study starts. Adjusted operating income was $132 million, 16.5% of revenue, up 9% year-over-year.

Guidance

• Revenue: Enterprise revenue guidance range is 7.4%-8%, narrowed midpoint due to currency and acquisition timing. Diagnostics guidance is 7.2%-7.8% (assuming ~4.5% organic growth). BLS guidance is 5.7%-7.1% (constant currency midpoint maintained).
• EPS: Adjusted EPS guidance is $16.15-$16.50, with a midpoint implying 12% growth.
• Free Cash Flow: Guidance is $1.165 billion-$1.285 billion, narrowed range with raised midpoint based on strong cash flow generation.

Risks

• PAMA Impact: Potential $100 million top-line impact, with efforts to mitigate via LaunchPad and AI initiatives, guidance to be provided in February 2026.
• Early Development Delays: Revenue softness in Early Development led to site consolidation and divestitures, affecting ~$50 million in annual revenue.
• Foreign Exchange: Unfavorable currency impacts on BLS revenue guidance due to timing of acquisition revenue and currency fluctuations.

Question and Answer

• Q: Understanding revenue and updated guidance, especially currency and acquisitions A: $13 million of the guidance change came from foreign exchange, the rest from acquisitions (timing related). Organic volume growth is seen, not due to ACA concerns but from organic demand.
• Q: Organic price/mix strength A: Organic volume increased 3.5%, price/mix rose 2.8% driven by Invitae and tests per session. Proactive mix growth supported by partnerships, aging population, and specialty testing.
• Q: Site consolidation in Early Development A: Delayed study starts in Early Development led to divestitures and site consolidation, expected to slightly improve operating income.
• Q: PAMA expectations and mitigation A: Working on mitigating ~$100 million impact via LaunchPad and AI initiatives, advocating for the RESULTS Act to address PAMA concerns, with guidance to be provided in February 2026.
• Q: Consumer-driven testing growth A: Strong growth in consumer business via on-demand platform and Ovia app, adding new tests like lead exposure and heart health tests, but not yet reported separately.
• Q: Diagnostics margin expansion A: 110 basis points of margin expansion in Diagnostics driven by Invitae, organic demand, LaunchPad savings, and weather favorability.
• Q: Hospital M&A criteria A: Deals include running hospital labs, reference work, and outreach, aiming for neutral to average margins over time through a combination of business segments.
• Q: BLS bookings between Central Lab and Early Development A: Central Lab book-to-bill is strong (trailing 12 months at 1.09), while Early Development is affected by delayed study starts despite strong RFPs and win rates.
• Q: Central Lab strength durability A: Central Lab grew 10% (7% constant currency), expected mid-single-digit growth for the full year, supported by large multi-year studies.